Bayer CropScience Resultados de beneficios anteriores
Pasado controles de criterios 6/6
Bayer CropScience ha aumentado sus beneficios a una tasa media anual de 3.7%, mientras que los beneficios de la industria de Chemicals han experimentado un crecimiento de 6.7% anual. Los ingresos han ido creciendo a una tasa media de 5.5% al año. La rentabilidad financiera de Bayer CropScience es de 21.5%, y sus márgenes netos son de 11.9%.
Información clave
3.72%
Tasa de crecimiento de los beneficios
3.72%
Tasa de crecimiento del BPA
| Crecimiento de la industria Chemicals | 17.68% |
| Tasa de crecimiento de los ingresos | 5.45% |
| Rentabilidad financiera | 21.46% |
| Margen neto | 11.93% |
| Próxima actualización de resultados | 26 May 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook
Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook
The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook
Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook
Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook
Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook
Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year
Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025
Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025
Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.Seeds, Traits And Biofuels Will Unlock New Value Pools
Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.Desglose de ingresos y gastos
Cómo gana y gasta dinero Bayer CropScience. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 25 | 56,206 | 6,704 | 7,462 | 0 |
| 30 Sep 25 | 55,718 | 6,089 | 7,540 | 0 |
| 30 Jun 25 | 57,566 | 5,925 | 7,574 | 0 |
| 31 Mar 25 | 54,734 | 5,680 | 7,527 | 0 |
| 31 Dec 24 | 52,172 | 5,207 | 7,208 | 0 |
| 30 Sep 24 | 51,152 | 5,796 | 7,116 | 0 |
| 30 Jun 24 | 49,948 | 6,662 | 6,965 | 0 |
| 31 Mar 24 | 51,062 | 7,405 | 6,902 | 0 |
| 31 Dec 23 | 52,942 | 8,030 | 7,684 | 0 |
| 30 Sep 23 | 53,772 | 8,444 | 8,020 | 0 |
| 30 Jun 23 | 52,119 | 7,841 | 8,299 | 0 |
| 31 Mar 23 | 51,397 | 7,582 | 8,616 | 0 |
| 31 Dec 22 | 51,205 | 7,524 | 8,381 | 0 |
| 30 Sep 22 | 50,727 | 7,027 | 8,313 | 0 |
| 30 Jun 22 | 49,859 | 6,942 | 8,027 | 0 |
| 31 Mar 22 | 47,344 | 6,453 | 7,836 | 0 |
| 31 Dec 21 | 45,048 | 5,545 | 6,549 | 0 |
| 30 Sep 21 | 44,329 | 4,246 | 6,090 | 0 |
| 30 Jun 21 | 44,494 | 4,951 | 5,858 | 0 |
| 31 Mar 21 | 42,613 | 4,931 | 5,726 | 0 |
| 31 Dec 20 | 39,913 | 4,627 | 5,706 | 0 |
| 30 Sep 20 | 39,271 | 6,457 | 5,559 | 0 |
| 30 Jun 20 | 38,918 | 5,909 | 5,703 | 0 |
| 31 Mar 20 | 36,094 | 4,745 | 5,729 | 0 |
| 31 Dec 19 | 29,294 | 2,864 | 5,437 | 0 |
| 30 Sep 19 | 28,505 | 2,116 | 5,580 | 0 |
| 30 Jun 19 | 25,256 | 1,497 | 5,427 | 0 |
| 31 Mar 19 | 31,754 | 3,371 | 6,010 | 0 |
| 31 Dec 18 | 28,639 | 3,045 | 4,621 | 0 |
| 30 Sep 18 | 27,226 | 2,877 | 4,476 | 0 |
| 30 Jun 18 | 28,505 | 3,356 | 4,392 | 0 |
| 31 Mar 18 | 27,167 | 3,001 | 4,327 | 0 |
| 31 Dec 17 | 26,375 | 2,769 | 4,280 | 0 |
| 30 Sep 17 | 28,203 | 3,030 | 4,242 | 0 |
| 30 Jun 17 | 26,796 | 2,715 | 2,507 | 0 |
| 31 Mar 17 | 28,153 | 2,910 | 4,129 | 0 |
| 31 Dec 16 | 40,105 | 3,323 | 4,219 | 0 |
| 30 Sep 16 | 32,030 | 3,342 | 3,519 | 0 |
| 30 Jun 16 | 38,027 | 3,215 | 4,116 | 0 |
| 31 Mar 16 | 27,838 | 3,151 | 4,073 | 0 |
| 31 Dec 15 | 37,919 | 3,278 | 6,458 | 0 |
| 30 Sep 15 | 38,569 | 3,554 | 6,469 | 0 |
| 30 Jun 15 | 39,222 | 3,814 | 6,433 | 0 |
Ingresos de calidad: 506285 tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (11.9%) de 506285 son superiores a los del año pasado (10%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de 506285 han crecido un 3.7% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de 506285 en el último año (28.7%) supera su media de 5 años (3.7% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de 506285 en el último año (28.7%) superó al de la industria Chemicals 9.5%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (21.5%) de 506285 se considera alta.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 07:51 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Bayer CropScience Limited está cubierta por 26 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Himanshu Binani | Anand Rathi Shares and Stock Brokers Limited |